- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced May 22, 2026, 1:17 AM EDT